Samuel M. Moskowitz

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Peter G. Middleton, Marcus Mall, Pavel Dřevı́nek et al. · New England Journal of Medicine · 2019 · 2.1K citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +16

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.4K citations · Full text

Life Sciences, Genetics, Pharmacology +14

Genetic adaptation by <i>Pseudomonas aeruginosa</i> to the airways of cystic fibrosis patients

Eric E. Smith, Danielle Buckley, Zaining Wu et al. · Proceedings of the National Academy of Sciences · 2006 · 1.4K citations · Full text

Life Sciences, Genetics, Microbiology +17

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

D. Keating, Gautham Marigowda, Lucy Burr et al. · New England Journal of Medicine · 2018 · 727 citations · Full text

Pharmacy, Molecular Genetics, Pharmacotherapy +13

PmrAB, a Two-Component Regulatory System of <i>Pseudomonas aeruginosa</i> That Modulates Resistance to Cationic Antimicrobial Peptides and Addition of Aminoarabinose to Lipid A

Samuel M. Moskowitz, Robert K. Ernst, Samuel I. Miller · Journal of Bacteriology · 2003 · 414 citations · Full text

Life Sciences, Microbiology, Antimicrobial Resistance +16